Insider buying last 90 days
No open-market insider purchases were filed for SDGR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SDGR insider filing, plotted on the chart in Gekko.Open SDGR in Gekko
NASDAQ: SDGR
Schrodinger (SDGR) Stock Analysis & Forecast
Oct 12 close
$25.91−1.37 (−5.0%)
Gekko Brief
AI summaryOct 12 closeSchrodinger moves this week on a mix of valuation commentary and analyst activity rather than company-specific news. One outlet flagged the stock as trading above its own GF Value estimate of $24.08 despite a GF Score of 72/100, citing insider selling of $2.3 million with no offsetting buying, while Argus lowered its price target to $30.00 against a share price of $27.28. A separate stock-grade summary cites an average analyst price target of $21.43 from 7 ratings. Comparative pieces also set Schrodinger alongside other healthcare-software names without new operational disclosures.
The stock closes at $25.91, down 5% on the day, but remains well above both its 50-day average of $22.85 and its 200-day average of $16.26, with the 50-day above the 200-day. The GekkoIndex reads 57.4, placing it in the Neutral zone, up 12.2 over five days. Price sits 16.9% above the Gekko Fair Value of $22.16. One-month, three-month and six-month returns stand at 36.2%, 60.6% and 126.3% respectively.
Earnings are scheduled for 4 November 2026, after the close, 22 days out and inside a typical 20-trading-day holding window; the last report showed EPS of $0.08 against an estimate of -$0.60, with a 13.8% reaction. Consensus among 6 firms shows 4 buy and 2 hold ratings, with a consensus target of $21.43, implying a consensus downside of -17.3%. Seasonality over 5 years shows an average 20-day return of 0.7%, positive in 3 of those years. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Schrodinger price vs fair value
Close $25.91200-day averageGekko Fair Value $22.16
Schrodinger quick facts
- Market cap
- $1.94B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.74
- Revenue, TTM
- $259.0M
- Profit margin
- -21%
- Dividend yield
- —
- Beta
- 1.62
- Volume
- 2.15M avg 3.52M
- 1-year return
- +25.5%
- Typical daily move
- ±9%
- Typical 20-day move
- ±11.9%
- 50-day average
- $22.85
- 200-day average
- $16.26
- Next earnings
- Nov 4 after close
- Shares outstanding
- 65.64M
Schrodinger swing-trade checklist
Schrodinger scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $25.91 is above the 50-day ($22.85) and 200-day ($16.26) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
57.4, Neutral
Reading 57.4 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
16.9% above
Price is 16.9% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Schrodinger stock chart and price history
Schrodinger closed at $25.91 on Oct 12, 2026, +25.5% over the past year, inside a 52-week range of $10.95 to $33.78.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +36.2%
- 3 months
- +60.6%
- 6 months
- +126.3%
- 1 year
- +25.5%
The full SDGR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SDGR in Gekko
Follow Schrodinger through every session
Put SDGR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SDGR in GekkoFree for 7 days. No credit card required.
About Schrodinger
Schrodinger builds a computational platform grounded in physics to help scientists identify promising new molecules, work that supports both drug development and materials research. The company is best known for applying this technology to speed up the search for viable compounds, serving customers across life sciences and materials science fields in the United States and in markets spanning Asia-Pacific, Europe, the Middle East and Africa.
Its business runs through two segments. The Software segment licenses its molecular discovery tools to companies working in life sciences and materials science. The Drug Discovery segment is focused on advancing its own pipeline of preclinical and clinical programs, pursued both independently and through partnerships, including a research collaboration and license agreement with Novartis Pharma AG aimed at progressing several development candidates.
Schrodinger was incorporated in 1990 and operates out of New York, New York. Its shares trade on the NASDAQ under the ticker SDGR.
- Listed
- NASDAQ
- Sector
- Technology services
- Industry
- Packaged software
- Website
- schrodinger.com
Schrodinger GekkoIndex: the smart money zone
Schrodinger’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.4, in the Neutral zone, up 12.2 points over five sessions.
57.4Neutral
Up 12.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | +2.6% | +5.6% | ||
| Accumulation | 295 | +1.0% | +2.8% | ||
| Neutral (current zone) | 318 | −0.2% | −0.2% | ||
| Distribution | 35 | −1.5% | −1.4% | ||
| Selling | 1 | Too few readings yet | |||
Average SDGR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the SDGR price, zone by zone.Track SDGR in Gekko
Is Schrodinger stock overvalued? Gekko Fair Value
Schrodinger trades 16.9% above Gekko Fair Value of $22.16, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Schrodinger shares are worth, recalculated every trading day.
$22.16
Gekko Fair Value, Oct 10, 2026
16.9% Overvalued
At the end of Aug 2026 the price was 1.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SDGR in Gekko
Schrodinger insider and Congress trading
No open-market insider purchases were filed for Schrodinger, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SDGR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SDGR, plotted on the chart in Gekko.Open SDGR in Gekko
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold SDGR.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Schrodinger earnings: next date and track record
Schrodinger reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$0.70
- Revenue estimate
- $48.55M
7 of 8reports beat the EPS estimate
±7%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Schrodinger reported solid momentum in Q2 2026 driven by 27% ACV growth, broad-based customer demand, product launches, and the launch of Bunsen, their agentic AI co-scientist. Management highlighted a continued shift to hosted licensing (hosted revenue 47% of software in the quarter, up from 31% year-ago), progress on converting customers toward a throughput-based hosted model, disciplined expense management with operating expenses down 6% YoY, and therapeutics portfolio advances including collaborations and clinical progress. Key commercial developments included a strategic software agreement with Bristol Myers Squibb to deploy Bunsen at scale and a new global collaboration with Simcere for therapeutics development. Management emphasized continued R&D-driven product launches (predictive tox, retrosynth) as major growth drivers and noted the long-term potential of predictive toxicology. The company reiterated its transformation toward a predict-first, computationally driven discovery model and indicated that hosted licensing will compress near-term revenue recognition but increase long-term recurring revenue capture.
- Risks flagged
- No quantitative forward-looking guidance was provided on the call. Risk items discussed or implied include: (1) short-term revenue growth being impacted by the transition to hosted licensing (ratable revenue recognition versus upfront), (2) long lead times for adoption and commercial validation of transformative products like predictive tox, (3) dependence on large customers (e.g., BMS) for scale and the concentration risk that may imply, (4) sensitivity to biotech funding and macro conditions (noted improvement but remains a cyclical risk), and (5) execution risk around converting customers to hosted and realizing expected throughput monetization.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.08 est −$0.60 | $58.89M est $47.19M | +13.8% |
| May 5, 2026 | −$0.62 est −$0.57 | $58.59M est $47.57M | +0.6% |
| Feb 25, 2026 | −$0.18 est −$0.19 | $87.20M est $83.76M | +12.9% |
| Nov 5, 2025 | −$0.45 est −$0.75 | $54.32M est $83.61M | −6.7% |
| Aug 6, 2025 | −$0.59 est −$0.83 | $54.76M est $50.35M | −1.4% |
| May 7, 2025 | −$0.64 est −$0.81 | $59.55M est $54.62M | +1.4% |
| Feb 26, 2025 | −$0.24 est −$0.38 | $88.32M est $83.20M | +5.7% |
| Nov 12, 2024 | −$0.52 est −$0.60 | $35.29M est $83.19M | +13.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Schrodinger stock forecast and analyst price targets
Analysts’ average 12-month price target for Schrodinger is $21.43, −17.3% from the last close, from 6 firms rating the stock in the last 90 days.
$21.43consensus 12-month target, −17.3% from the last close
Now $25.91Avg $21.43
Low $17High $30
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | BMO Capital | $30 | +15.8% |
| Sep 15 | Morgan Stanley | $17 | −34.4% |
| Aug 17 | BMO Capital | $24 | −7.4% |
| Aug 14 | UBS | $19 | −26.7% |
| Aug 13 | UBS | $19 | −26.7% |
−0.2%average 20-day move after past Neutral readings
+0.7%average move over the next 20 trading days in the last 5 years
±9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Schrodinger seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Schrodinger averaged +0.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.2% | 3 of 5 |
| Next 10 trading days | +1.9% | 3 of 5 |
| Next 15 trading days | +1.0% | 4 of 5 |
| Next 20 trading days | +0.7% | 3 of 5 |
| Next 30 trading days | −8.5% | 2 of 5 |
For scale, SDGR’s typical 20-trading-day move in either direction is about 11.9%.
Schrodinger market cap and key statistics
Schrodinger’s market cap is $1.94B and revenue of $259.0M over the last twelve months.
Valuation
- Market cap
- $1.94B
- EPS, TTM
- −$0.74
- Gekko Fair Value
- $22.16
Trading
- Volume
- 2.15M
- Avg volume, 20 days
- 3.52M
- 52-week high
- $33.78
- 52-week low
- $10.95
- Shares outstanding
- 65.64M
Financials
- Revenue, TTM
- $259.0M
- Profit margin
- -21%
- Return on equity
- -16.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.62
- Typical daily move
- ±9%
- Typical 20-day move
- ±11.9%
Schrodinger stock news this week
Coverage of Schrodinger this week reads negative: 0 positive, 1 neutral and 3 negative headlines.
- Reviewing Claritev (NYSE:CTEV) and Schrodinger (NASDAQ:SDGR)Defense World, Oct 12
- Analyzing Teladoc Health (NYSE:TDOC) & Schrodinger (NASDAQ:SDGR)Defense World, Oct 12
- Schrodinger Inc (SDGR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 72/100GuruFocus, Oct 10
- Schrodinger, Inc. (SDGR) Stock ForecastsYahoo! Finance Canada, Oct 9
- Schrödinger, Inc. (SDGR) Options ChainYahoo! Finance Canada, Oct 8
- Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?Zacks Investment Research, Oct 6
Schrodinger peers
Schrodinger’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 21.7% above |
| PLTRPalantir Technologies | Distribution | 22.3% above |
| ORCLOracle | Neutral | 24.3% below |
| PANWPalo Alto Networks | Neutral | 21.6% above |
| CRWDCrowdStrike | Neutral | 23.7% above |
| CRMSalesforce | Neutral | 3.6% below |
A peer links to its own page where one exists.
Schrodinger stock FAQ
What is Schrodinger’s market cap?
Schrodinger’s market cap is $1.94B at the Oct 12, 2026 close of $25.91, with 65.64M shares outstanding.
What is the Schrodinger stock forecast?
The consensus analyst 12-month price target for Schrodinger is $21.43, −17.3% from the last close. Of the 6 firms that rated the stock in the last 90 days, 4 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Schrodinger stock overvalued or undervalued?
On Gekko’s estimate Schrodinger is overvalued: the Oct 12, 2026 close of $25.91 is 16.9% above Gekko Fair Value of $22.16. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Schrodinger report earnings next?
Schrodinger is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$0.70 per share on revenue of $48.55M. Schrodinger beat the earnings estimate in 7 of its last 8 reports, moving 7% on average across the report.
What is Schrodinger’s 52-week high and low?
Schrodinger’s 52-week high is $33.78 and its 52-week low is $10.95; it closed at $25.91 on Oct 12, 2026, +25.5% over the past year. Over the last five years the shares peaked at $59.87 on Nov 3, 2021.
Is Schrodinger stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Schrodinger the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.